Vanfleteren Pieter SRL
Vanfleteren Pieter reported total assets of 52,894 € at the end of the 2025 financial year (annual accounts filed with the NBB on 23 Jun 2026).
The score of Vanfleteren Pieter shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -75 % Total assets -66 %
Accounts of the company itself (not consolidated).
The full file covers 7 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Vanfleteren Pieter's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 23 Jun 2026
- Year ended 31 Dec 2024filed on 28 Jun 2025
- Year ended 31 Dec 2023filed on 21 Jun 2024
- Year ended 31 Dec 2022filed on 18 Jun 2023
- Year ended 31 Dec 2021filed on 17 Jun 2022
Vanfleteren Pieter's financial analysis
- Solvency69.8%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Vanfleteren Pieter
Vanfleteren Pieter's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0698.650.418
- VAT number
- BE0698650418
- Peppol
- Registered · 0208:0698650418 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 20 Jun 2018
- Registered office
- 2600 Antwerp
- Latest accounts
- 2025 · filed on 23 Jun 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Vanfleteren Pieter (SRL) has been based in Antwerp since 2018, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 25,998 € and equity of 36,898 €; its revenue is not published. Its solvency stands at 69.8%, above the median of its sector (44.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Vanfleteren Pieter
Companies in the same business, of comparable size and area, outside its group.
- Yascare Retail sale of pharmaceutical products Uccle · balance sheet 34,424 €
- Helephar Retail sale of pharmaceutical products Wingene · balance sheet 55,332 €
- Siga Pharm Retail sale of pharmaceutical products Uccle · balance sheet 46,193 €
- Itipharma Ghyselen Retail sale of pharmaceutical products Soignies · balance sheet 61,934 €
- MGS Pharma Retail sale of pharmaceutical products Stavelot · balance sheet 68,803 €
- Tilosa Retail sale of pharmaceutical products Lokeren · balance sheet 70,195 €
- LEJV Retail sale of pharmaceutical products Bertrix · balance sheet 34,528 €
- NT Farma Retail sale of pharmaceutical products Mouscron · balance sheet 56,255 €
Frequently asked questions about Vanfleteren Pieter
What is the revenue of Vanfleteren Pieter?
Vanfleteren Pieter files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Vanfleteren Pieter?
In Belgium, the VAT number is the company number prefixed with BE: BE0698650418 for Vanfleteren Pieter, if the company is VAT-registered. Its company number (CBE) is 0698.650.418.
Where is the registered office of Vanfleteren Pieter?
According to the CBE register, the registered office of Vanfleteren Pieter is in 2600 Antwerp.
What is the equity of Vanfleteren Pieter?
At the close of the 2025 financial year, the equity of Vanfleteren Pieter amounts to 36,898 €, a solvency of 69.8% of total assets.
Who manages Vanfleteren Pieter?
The register lists 1 active mandates at Vanfleteren Pieter. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Vanfleteren Pieter
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →